Bright Minds Biosciences Inc. (DRUG)
Market: NASD |
Currency: USD
Address: 19 Vestry Street
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Show more
📈 Bright Minds Biosciences Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$78.19
-
Upside/Downside from Analyst Target:
198.90%
-
Broker Call:
11
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.200000 |
- |
2023-07-14 |
- |
Stock split |
|
Total Amount for 2023: $0.200000 |
📅 Earnings & EPS History for Bright Minds Biosciences Inc.
| Date | Reported EPS |
|---|
| 2025-05-15 | -0.42 |
| 2025-02-13 | 0.01 |
📰 Related News & Research
No related articles found for "bright minds".
